B. Riley Comments on Novavax's FY2027 Earnings (NASDAQ:NVAX)

Key Points

• B. Riley has increased Novavax's FY2027 earnings per share estimate from $0.31 to $0.33, maintaining a "Buy" rating on the stock.
• Novavax reported quarterly earnings of $0.62 EPS, significantly surpassing analyst expectations of (0.07), with revenues of $239.24 million for the quarter.
• Analysts have mixed ratings for Novavax, with two sell ratings, two hold ratings, and four buy ratings, leading to an average rating of "Hold" and a consensus target price of $15.86.

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Analysts at B. Riley increased their FY2027 earnings per share estimates for Novavax in a research report issued to clients and investors on Thursday, August 7th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings per share of $0.33 for the year, up from their previous estimate of $0.31. B. Riley currently has a "Buy" rating on the stock. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax's FY2028 earnings at $0.28 EPS and FY2029 earnings at $0.81 EPS.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%. The firm had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. During the same quarter last year, the company posted $0.99 earnings per share. The business's revenue was down 42.4% on a year-over-year basis.

A number of other equities analysts have also issued reports on the company. Citigroup started coverage on Novavax in a report on Tuesday, June 17th. They set a "sell" rating and a $6.00 price target on the stock. Bank of America reduced their price objective on shares of Novavax from $10.00 to $9.00 and set a "neutral" rating for the company in a research report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Novavax has an average rating of "Hold" and a consensus target price of $15.86.

Novavax Stock Performance

NASDAQ NVAX opened at $8.37 on Monday. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93. Novavax has a 52-week low of $5.01 and a 52-week high of $15.22. The business's 50-day moving average price is $6.98 and its 200 day moving average price is $7.18. The firm has a market cap of $1.36 billion, a P/E ratio of 3.67, a P/E/G ratio of 0.10 and a beta of 2.50.

Institutional Investors Weigh In On Novavax

A number of hedge funds and other institutional investors have recently modified their holdings of NVAX. Sanofi acquired a new stake in shares of Novavax during the 4th quarter valued at approximately $55,319,000. Park West Asset Management LLC acquired a new stake in shares of Novavax during the 1st quarter valued at approximately $16,210,000. Deep Track Capital LP acquired a new stake in shares of Novavax during the 4th quarter valued at approximately $16,080,000. Jupiter Asset Management Ltd. lifted its position in shares of Novavax by 195.9% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 880,410 shares of the biopharmaceutical company's stock valued at $5,547,000 after acquiring an additional 582,858 shares during the period. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Novavax during the 2nd quarter valued at approximately $3,382,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.